Molecules "imagined" using advanced artificial intelligence show promising results in pre-clinical experiments

For readers unfamiliar with the drug discovery and development process, it is worthwhile to point out that the pharmaceutical industry is one of the most inefficient and risky industries on the planet. The efficiency of the industry has been on the decline since the 1950s. It costs over $2.6 Billion to bring the New Molecular Entity (NME) to the market. And despite the many advances disrupting other industries including personal computing, the Internet, and genome sequencing, the cost to develop a drug is steadily increasing. This is one of the reasons why most industry experts are skeptical about the promises of deep learning.